EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

March 16, 2022

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 63 min

Earnings Call Speaker Segments

Nicola Fiore

operator
#1

Good afternoon, everyone, and welcome to El.En's conference call on the financial results for Fiscal Year 2021. <<foreign_lang>> All right. Let me begin once more. Good afternoon, everybody, and welcome to El.En's conference call covering the Fiscal Year 2021 financial results. This call is being recorded, so there will be a chance to ask questions at the end of the conference. Joining me are Andrea Cangioli, El.En's CEO, and Enrico Romagnoli, Chief Financial Officer and Investor Relation. Before getting started, please note that management will make remarks on this conference call regarding future expectations, plans and prospects, and these are forward-looking statements. Certain statements on this call, including those concerning the company's belief, objectives, estimates, or expectation of possible future results or events, constitute forward-looking statements. Forward-looking statements carry known or unknown risks, including general economic and business conditions and conditions in the industry in which the company operates, and may be affected if the assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed, said or implied by such forward-looking statements. The company assumes no obligation regarding the contents, nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Nicola Fiore

operator
#2

If you’d like to ask questions, please book your question in Bianca Fersini Mastelloni’s chat. She’ll be glad to introduce you in the order bookings are made. At this point, though, I’d like to hand the floor to Andrea Cangioli. Please go ahead, Andrea.

Andrea Cangioli

executive
#3

Thank you, Nicola, for that introduction. I trust everyone is doing well. My thanks to Bianca as well, and welcome to all of you. We appreciate your participation on this call, which follows the publication of our 2021 full-year financials. Joining me here is Enrico Romagnoli, who will walk you through the specifics of how we performed financially. The 2021 results came in extraordinarily strong. Revenue rose 40%, and over the last 2 years average growth reached 19.4%, even with the pandemic's impact. Operating profit and net profit increased in line, each posting average growth above 30% compared with 2019. To capture our revenue generation performance in one figure: consolidated EBITDA stood at EUR 80 million for 2021. We feel both pleased and proud about these remarkable achievements, and we are grateful to every person across the El.En Group whose valuable efforts are making it all happen. What's more, we are confident that thanks to their knowledge, dedication and capabilities, our people form the cornerstone of the structure we have been building and steadily expanding through the years, and we intend to raise it further going forward. Right now, I would like to hand the floor directly to Enrico Romagnoli for the financial details.

Andrea Cangioli

executive
#4

I’ll return afterward with a handful of broader remarks about how we performed and what we expect. Thanks, Enrico.

Enrico Romagnoli

executive
#5

Thanks, Andrea. Morning, everyone. As Andrea mentioned, 2021 was an outstanding year financially. On this slide, you can see 2021's key figures: sales above EUR 571 million and EBIT of EUR 64.8 million. Double-digit growth across most segments — industrial up 45% and medical up 36% versus 2020. And our annual average growth over 2019 comes to 13% for medical and 24% for industrial. Gross margin profitability also improved from 2020 to 2021. Medical rose from 41% to 44.8%, and industrial from 26.6% to 27.9%. The full income statement shows the progression, the increase versus 2020 and versus 2019. And the real proof of how solid these results are lies in the comparison with 2019, the last year before the pandemic. Despite the crisis's heavy impact, average growth from 2019 to 2021 was 19.4% for revenue, 30.3% for EBIT, and 32.2% for net income. In 2021, we also saw improvement in gross margin, profitability, total value, because the total amount of sales increased, but also in relative terms, thanks to the mix of products sold within each individual sector, savings on purchases from efficiencies deriving from higher volumes, and the strengthening of the U.S.

Enrico Romagnoli

executive
#6

In dollar terms, along with a rise in dollar-denominated turnover in North America. Operating costs were also kept in check—especially sales and marketing, thanks to the sharp cutback in travel, trade fair, and congress spending—and EBITDA came in at EUR 80.1 million, a 14% EBITDA margin, versus EUR 40.8 million in 2020. After amortization, depreciation, and provisions—which rose both because of the investment volume of prior years and because of the prudential provisions set aside during the year—EBIT was positive at EUR 64.8 million, up from EUR 30.1 million in 2020, with an EBIT margin of 11.4%, an improvement over last year's 7.4%. Pre-tax income was positive at roughly EUR 66.4 million, and with a tax rate of 26%, the net result was 45.4% of euro (sic) EUR 45.4 million, compared with EUR 20.3 million a year earlier. And the impact on turnover went from 5% to 8%. In Q4 as well, we saw strong growth in sales and in profit, with profitability in EBIT terms above the year's average, as is usual, since seasonally Q4 is typically the strongest quarter of the year for both sales and profitability.

Enrico Romagnoli

executive
#7

On the balance sheet side, our net financial position came in positive at EUR 115.7 million, which is an increase of EUR 51.5 million versus December 2020 and up EUR 41 million versus September 2021. Cash generation was excellent even with the substantial fixed asset investment we made, totaling EUR 23 million during the period. We observed an improvement in the ratio of net working capital to sales, which went from 27% down to 25%, along with a sharp rise in the EBIT on net capital employed ratio, helped by the EBIT increase and by cash generation during the year. On the cash flow side, over the year the group produced cash from operating activities, while there was a cash absorption of EUR 33 million caused by the working capital increase, which is physiological in this rapid growth phase. And we have positive cash flow for other current payables and receivables, mainly driven by the growth in advances received from customers, a practice that is particularly relevant in China. We had cash absorption from investments, as already mentioned, of EUR 23 million, and the largest single investment during the year was the new Cutlite Penta building in Prato for EUR 5 million, acquired through a leasing.

Enrico Romagnoli

executive
#8

El.En and its subsidiaries distributed dividends totaling EUR 9 million, and there was additionally a capital increase of EUR 4 million stemming from employee stock option exercises. In the medical sector, revenue by business accounted for 54.5% of group revenues in 2021, reaching a total of EUR 311 million, with a 13% CAGR over 2019. The aesthetics segment delivered the strongest results, posting a 22% CAGR over 2019 and sales amounting to EUR 198 million. Three main families of laser systems for hair removal proved pivotal for the group: Mediostar by Asclepion, and the Motus and Again by Deka. We observed recovery relative to 2020 in the therapy segment, up 76% over 2020, and surgery up 18% over 2020 — the area hit hardest by COVID's effects, which shone again during the year, with revenues in therapy set above 2019 levels and the prospect of a near-term recovery for surgery, or a return to the record levels of 2019. Systems for surgical application in the urological segment, for stone removal and for treatment of benign prostate hypertrophy, grew in the installed base over the year and will generate future income thanks to the consumable.

Enrico Romagnoli

executive
#9

To start, the group makes single- and multiple-use optical fiber, and that fiber is meant to be used in every single surgical procedure. Consumables and maintenance get counted in the service segment. Now for the industrial sector — in 2021, industrial growth accounted for 45.5% of group revenue, totaling EUR 216 million, with a CAGR of 28% over 2019. The laser cutting sector's disruptive growth carried on through the year, with EUR 216 million in revenues coming from both the Chinese and the Italian organizations engaged in sheet metal laser cutting. We should note that Cutlite Penta, which is active in Italy and Europe in the laser cutting sector, posted an extraordinary 68.8% growth, making a decisive contribution — over the group. Market momentum also reached the group's Brazilian branch, which managed to double its turnover and delivered a positive contribution to group profitability. Inside the industrial sector, the marking business trended positively, and we highlighted Lasit's performance, which showed a turnover of EUR 18.1 million versus EUR 14 million last year. There was an increase as well in the 2 other sectors of laser sources and service.

Enrico Romagnoli

executive
#10

And finally, looking at the breakdown by area: growth is substantial across every geography where the group does business, and Europe's performance really stands out in the medical sector at plus 20%, while in the industrial sector the strongest result came in Italy. Andrea, over to you for the presentation.

Andrea Cangioli

executive
#11

Thank you. There's a voice coming through underneath — please switch off the microphone. So, thank you, Enrico; please take this now — I'll discuss the guidance afterward. As you can see, it's difficult to identify any flaws in how we performed during 2021, which is essentially outstanding across every financial and business metric. Allow me to bring you up to date on where we stand at present and on what our business can achieve. I'll walk through an overview of our markets, our present positioning, the impact of the Russian/Ukrainian conflict, other factors that could influence how we are currently performing, and I'll lay out for you the basis and the boundaries of the guidance that appears on the screen in front of you now. After that, I'll say a few words about our laser cutting business, with particular attention to our operations in China, and about CapEx. As you're aware, the broader picture at EL.En shows that we operate in 2 very different markets: laser and energy-based systems for medical applications, and laser systems used in manufacturing. We chose to serve these 2 markets from the shared foundation of our expertise in laser technologies, and over the years we adjusted our organization, our products and our activities to the specific market segments we judged most promising for uptake of the technologies we excel at developing.

Andrea Cangioli

executive
#12

The robust demand that we saw over the past 18 months is validating the ambition we shared with you — the ability to stay on a trajectory of fast expansion. Medical, aesthetic, and laser applications are addressing a broad and expanding set of social needs: improving how we look, in the body and in the face, effectively, noninvasively, and also cost effectively, while pushing back against the science of aging. At the same time, our technological offering meets this expectation, and via new affordable, effective, and reliable procedures and systems, it is opening up further opportunities — new possible and desirable applications that serve the wish to look better and younger. The market for aesthetics overall, and for aesthetic devices specifically, is thriving and is expected to keep up its growth momentum in the years ahead. Surgical laser applications are increasingly in demand to substitute minimal invasive procedures for traditional surgeries, delivering excellent outcomes with less discomfort and fewer side effects for patients, plus improved ROI for the investor or perhaps even better, lower cost for public national hospital systems. This market too is projected to expand rapidly, again driven by technological innovation. Looking only at the system sales portion of our revenues, medical aesthetics and surgery were worth EUR 198 million and EUR 45 million respectively, which represented 39% and 9% of our total system sales, again respectively.

Andrea Cangioli

executive
#13

When it comes to industrial applications, we're playing in a wider market — specifically the broader market for manufacturing systems, which hasn't been seen as particularly attractive, especially in Western countries, amid the localization of a number of manufacturing processes at this stage. Incidentally, we made the decision back in 2007 to diversify our localization. Over the past several years, the market for sheet metal laser cutting — the biggest of our application segments — has been expanding quickly, and it should continue its growth phase thanks to how the technology is evolving, which at the same time is enabling greater performance when it comes to the speed of manufacturing processes and cost reduction. Together, these 2 effects are boosting the count of potential buyers for our systems among the traditional users of laser cutting systems, speeding up replacement of the installed base because of rapid technological — please — because of rapid technological obsolescence, and last but not least, enabling the technology to be deployed in new application areas that, only as a consequence of the technological shift, are now prepared to adopt laser systems in their processes. Those are the reasons behind the anticipated growth in this market's size. The laser market is also in very good shape, benefiting from the growing need to identify parts and assemblies within the most advanced manufacturing systems.

Andrea Cangioli

executive
#14

Laser markers represent a flexible, effective, and eco-friendly answer, and acceptance of them keeps rising across manufacturing. Connecting that directly to our market—these expanding markets and our business—laser cutting systems generated EUR 215 million in revenue during 2021, equal to 43% of our total consolidated system sales, while market systems brought in EUR 30 million, about 4% of all group sales. Taking into account how our end markets should behave and where we stand competitively in each of them—given how wide and deep our product range is and how our distribution network is set up overall—our operational forecast for 2022 anticipates continued rapid expansion of the business across every segment. Early 2022 is bringing one more meaningful, let's say reassuring, factor to the present outlook: the record level of order backlog, which carries 2021's positive momentum into 2022—not just through expectations and how the market trend is perceived, but also through a solid foundation of orders to be delivered as sales in the coming months. And to round out the good news, it looks like in Western countries the path out of the pandemic is growing broader and smoother, with all the benefits that such a return to normality will bring to our lives and life.

Andrea Cangioli

executive
#15

We feel strong and confident. That said, we should be transparent with you: 2 very powerful sources of uncertainty are casting a shadow—or could cast a shadow—on the very bright picture we've been presenting, and I mean the supply chain problems and the Russian/Ukrainian war. And under the broader heading of supply chain difficulties, several issues have been holding us back over the last month and are likely to keep affecting our operations and our business going forward. There is now evidence of fairly strong inflation—a very strong inflation when it comes to gas and power supply. This will bring cost increases for us, both in cost of goods sold and in operational expenses. Heating, air conditioning, driving, shipping—just to name a few basic services whose costs are rising sharply. The rapid growth in our business volumes let us in 2021 overcome most of the material cost increases. But even though we're quoting more growth for 2022, we have evidence that in the near future we won't be able to offset cost increases with higher volumes. We are planning to pass cost increases through to our sales prices, and we've already begun doing so.

Andrea Cangioli

executive
#16

Yet that isn't always realistically achievable or suitable in every single trade deal. And when material shortages arise, cost isn't automatically the biggest issue. Because our bills of materials contain a very wide range of materials and components, we've been hit by shortages across multiple parts—everything from the well-known chipset to capacitors, plastic molded parts, and repairs components, all of which are essential for a particular laser category over these recent quarters—and we're missing quotes for our labs. Sourcing, and sourcing on time, has been difficult, and being able to receive certain ordered material promptly and dependably has been, and remains, a constraint on our capacity—on ramping production volumes up the way we'd like. The world is striking us and everyone; European people were psychologically put first in a position of helplessly watching such an unreasonable shame unfold next door. On the business side, we're facing the effects—certain effects that are definite: no more sales in the area for a while, plus a highly uncomfortable feeling of uncertainty regarding what the war's outcome and consequences might be. For us, both the Ukrainian and Russian markets are very interesting, particularly in the medical aesthetic portion of what we offer.

Andrea Cangioli

executive
#17

Trade between us and those regions accounts for no more than 2% of consolidated sales. Back in 2022, we had anticipated a sharp increase in sales volume across these areas. Even so, we are not discussing any particularly large effect on our sales overall. As for broader consequences, we Italians and Europeans are already suffering because of the energy bill and because of refugees who are fleeing. It is our strong hope that this war ends swiftly, sparing the lives currently being lost and lifting that feeling of uncertainty and unease which certainly does not help our markets and will not do so going forward. At the moment we chose to disclose our 2022 guidance, we opted to share with you the growth trajectory that the market conditions we are actually seeing are sketching out, and that trajectory is very positive. We also wanted to share it and to make it clear that these growth expectations depend on the general market, economic and international relations persisting as they are today, given that the war and the supply chain problems could, together or on their own, alter the frame of reference within which we are currently operating. With that assumption in place, we delivered what I consider the most aggressive initial guidance EL.En has ever released, for consolidated revenue growth above 10%.

Andrea Cangioli

executive
#18

As for the EBIT growth that the rise in sales is expected to imply, we can't be more precise about that, given the uncertainty around material costs and availability. This guidance incorporates a solid growth projection for our sheet metal laser cutting business, which is carried out by our Italian subsidiary, Cutlite Penta, and by our Chinese organization led by our company based in Wenzhou, which also has production facilities in Wuhan and Linyi. Over the last few years, the control structure for this business has been qualified — first by liquidating our minority Chinese partner, and then by concentrating all the other companies, including the Italian operation, under the Wenzhou company, creating a well-identified and separated division. In fact, during the Chinese New Year break, Penta Wenzhou succeeded in transforming its status into a joint stock company — a fairly complex procedure in China, which among other things included the re-auditing of the financials for the last 3 years in compliance with international accounting standards, taking into account the practice followed in China by companies listed on regulated markets. The transformation into a joint stock company is a necessary condition on the path toward a possible IPO of the business unit, which — once this further step is completed — is now one of the strategic options that can be implemented in pursuing our ambitious growth targets in the business.

Andrea Cangioli

executive
#19

I wanted to show you — Enrico, can you take the slide down, please? I wanted to show you a very short clip of our 40-kilowatt system, which is the top of the range in China. And here you can see it cutting 40-millimeter mild steel at 2.1 meters by minutes. As I said earlier, for us, because 5 years ago, this is like flying a rocket. And it's something that was simply unbelievable a few years ago — to cut with this speed, with this quality, mild steel of 4 centimeters of thickness. I understand this is not necessarily very alluring. But I wanted to give you a flavor of what the technology can do, and how the expectations on this market are tied to a very rapid technological improvement, and that has completely changed the face of the business and the ability of our system to perform cutting procedures within the manufacturing world. A few words on CapEx. CapEx for the year 2021 was around EUR 21 million, out of which EUR 15 million were dedicated to the expansion of our production capacity by purchasing, building, expanding and refurbishing our new plants. About 2 more million were expensed in other refurbishing activities for our older plants.

Andrea Cangioli

executive
#20

And lastly, $4 million went into ordinary investment for toolings, vehicles, software and other — and other small investment. Capacity expansion work is also going to happen at several of our locations in 2022. In Samarate, where Quanta System operates and where we refurbished our second building. In Wuhan, where we are finishing our new plants, and here in Calenzano, where certain areas of our plants will be expanded in the near future. As of today, capital expenditure for 2022 is expected to be in the neighborhood of EUR 15 million. Of course, this is subject to adjustment if, like in the past, capacity expansion opportunities appear alongside continued revenue growth — growth that most of our businesses have experienced recently. One very final word on our commitment to pursuing the sustainability targets that our plan provides for, which, by the way, form part of the valuation metrics for management, including myself. We are allocating adequate resources both to disseminate the ESG culture within the organization and also to improve the ratios granted by the relevant institutions. Thank you for your attention. I am at this point done with the presentation, and we are available for answering your questions.

Bianca Fersini Mastelloni

operator
#21

Andrea, there's a question coming in from Francois Robillard over at Intermonte.

François Robillard

analyst
#22

Let's start with your sales growth target for 2022. From what I gather, you're expecting some continued strong growth on the medical side, and you also had some positive things to say about the industrial side. And then there's the situation right now in China, especially — and what your competitors are saying about laser cutting, metal laser cutting in China, seems to point toward a more cautious expectation? Could you just walk us through a bit your expectation for each segment? Then just a quick follow-up on your EBITDA target. I understand you don't want to give many precise indications for now at the margin level as well. What can we expect a bit more precisely — something north of EUR 70 million out of expectations for now? Just give us some more color on this. And then on the working capital, I saw that you're — for the full year 2021, you had a positive contribution from other items, especially other liabilities. Can you just give us some more color on that?

Andrea Cangioli

executive
#23

Francois, yes — naturally we don't share a lot of specifics, but when we say we expect revenue growth north of 10%, that means we're anticipating that kind of growth across most of our segments. Naturally, a few segments are performing even better. For example, we anticipate very strong growth in sales of aesthetic devices in the United States. We have experience with, and still forecast, softer growth in Japan for medical devices. We hold very strong expectations for Europe and the Middle East and for the body shaping market, and very strong expectations for the consumable tied to sales of the urological system. As for the industrial market, China was extremely brilliant during the first 6 months of 2021, and after that the growth came down. We have very good and strong expectations based mainly on what I have just been showing you. On the fact that we lead the pack — leading the market in the high-power application segment — and we expect to be able to capitalize on this segment's growth. And I believe that within this specific segment, we could — we identified a very interesting growth path.

Andrea Cangioli

executive
#24

The guidance and the model we put into that guidance were prepared before yesterday. We've now learned that COVID is hitting certain areas again. We've also received word from our suppliers—just so you're aware of how things are connected—that because of the lockdowns in China, they'll delay supplies of certain electronic parts, which will as a consequence mean delays in deliveries of certain material to us. So, I mean, the overall picture of the Chinese situation is less positive than we were hoping. Nevertheless, our sales plan, which was studied and discussed with our sales force in China, is still extremely positive regarding the ability to keep growing in this market segment. Working capital—your last question, yes, we did very well, and maybe we did even better than expected concerning working capital. This is tied to the circumstance—I mean, it's not a circumstance that took place over a short period, but a persistent circumstance of having a very large amount of orders and backlogs. And especially in the industrial laser system market, those come with a down payment, which helped us increase the after debt.

Andrea Cangioli

executive
#25

We saw a rise in the tens of millions, and that accounts for most of the light blue bar you see making a positive contribution to the net financial position, which is countries consisting of this customer down payments. Naturally, that figure will remain at that level only if we keep up the same volume of -- the same volume of down payments all year long, and that is unlikely to occur, particularly in Italy, where a lot of these down payments were linked to the so-called 4.0 -- 4.0 tax cut, which I expect will not vanish entirely but will gradually decline over the course of the year.

Bianca Fersini Mastelloni

operator
#26

Andrea, Marco Riva has a question for us.

Analyst

analyst
#27

Yeah, so if we look at what’s happened recently, even with stronger growth returning to a normal range for the industrial sector, you’ve still delivered an increase in overall margin. So the question is whether that depends on leverage, product mix—for example, shifting toward more powerful sources, laser sources—or what exactly it means, because historically more industrial sales have meant lower margin. And do you think it will be possible to pass the major cost you mentioned earlier into prices if you see a problem—if you expect a problem—or do you think that’s easy to do?

Andrea Cangioli

executive
#28

And apologies, Francois, since this formed part of your second question and I didn't address it. Now, though, I can respond regarding both industrial points. Naturally, you must bear in mind that we operate in a highly competitive marketplace where price rivalry exists, and we focus on particular market segments so as to steer clear of intense price competition that would damage our margins. China especially is a market we most likely could not win. Yet, as I mentioned, the substantial order intake meant pricing pressure eased for us. In industrial too, the additional volume growth we have planned, in both China and Italy, manages somehow to offset cost inflation. And I think that during 2021, and in 2022 as well, the cost efficiencies we are seeing in the industrial production process are contributing to this modest yet meaningful margin improvement. Whether we can pass a cost increase through to the price charged to each customer is always extremely hard to predict beforehand, since it hinges on the precise market conditions at the moment you are required to do so.

Andrea Cangioli

executive
#29

Take this year, 2021, for example: customers came to us and paid us to supply devices under any terms whatsoever, since their usual suppliers couldn't get deliveries to them on time. In that situation, there's no debate. If I want to obtain 10% -- or rather, if I get -- if my aim is to secure the cost and a price increase, I secure it. In another market climate, where competition is stronger and demand pressure is lighter, reverting our cost into our price could get tougher. It all boils down to grasping how these events -- inflation, the material shortage, the war in Russia -- will affect the business picture as a whole. Should favorable business conditions persist, replicating and even bettering 2022's results poses no difficulty for us. If the picture shifts, then carrying out each of the things we are managing quite successfully at present will be hard. So at this moment, as far as I can see today...

Bianca Fersini Mastelloni

operator
#30

Andrea, there’s another question coming in from Andrea Bonfa at Banca Akros.

Andrea Cangioli

executive
#31

Yeah, yeah. Okay, hold on — give me a moment to wrap up my response to the...

Bianca Fersini Mastelloni

operator
#32

Oh, my apologies—sorry about that.

Andrea Cangioli

executive
#33

The only — the only thing I'd say is that, with the situation as it stands and with the effects we're seeing today from these 2 issues, we're very optimistic, because we've managed to overcome any problems, and where problems did come up — I mean, they were minor problems relative to the biggest growth, the biggest improvement in results that we've been able to achieve. But of course, that's today, and we hope nothing changes. And in particular — we're particularly concerned about how the war evolves and its consequences, since it's very close to us and very close to North. Excuse me.

Bianca Fersini Mastelloni

operator
#34

Andrea?

Andrea Bonfà

analyst
#35

Okay. Andrea, if I could, I'd like some detail on how China performed during the first couple of months. It was positive, especially given that the comparison base was harder. Then you were right to note that we're in a competitive industry, but this year the U.S. dollar should help at least indirectly, right? And a technical point: I saw that minorities declined in the H2. If you could comment on that — I think it may be partly tied to China — but if you could remind us how that item works. And a brief update on the new machine you're launching in 2022, and in which market. I'm referring perhaps in particular to the one for acne treatment in the U.S., which is awaiting FDA approval? And then I noticed your D&A was strongly up in Q4. And if you could maybe disclose what the level of bad debt was, because I think that is included?

Andrea Cangioli

executive
#36

Andrea, I missed the final question. What is it that has risen sharply?

Andrea Bonfà

analyst
#37

Depreciation and amortization were up quite a bit. I understand that in your line, you're including bad debt there — is there anything worth mentioning in that specific item?

Andrea Cangioli

executive
#38

Hopefully I noted all of your question properly — if not, just remind me. Chinese performance. Performance in China during the first 2 years is always barely relevant for the business, since in the first 15 days they are waiting to head off for the holidays, and then February marks the start of the holidays. So the results we achieved match our expectations, match our budgets, and comply with the overall guideline — the guidance we gave you. On — let me see — on the decrease in minorities during the second half. Yes, that stems from the fact that financial performance in the second half was weaker at the companies where our minorities are larger. And the companies where our minorities are larger are the Japanese company with us, which performed rather weakly, cutting its revenues in the second half of 2021. And also the Chinese ones, where actually minorities are up around 8% — 5%, sorry, but they are quite significant in volume. The results — the financial results at the Chinese subsidiaries in the second half were not especially good, also because of the effects of the change in estimation that we had to carry out in the financials.

Andrea Cangioli

executive
#39

So that's why you're seeing a really big D&A figure in the quarters. It comes from how the Chinese evaluate certain items, such as warranty and bad debt, and we had to make adjustments to those in Q4 in line with the Chinese method for handling these 2 things. On new systems, the biggest launch in terms of innovation content for 2022 so far is a new CO2 laser, and it's combined with an added 1470 wavelength that, alongside the usual ablation effect tied to our CO2 laser systems, brings in our heating, deep heating device. The mix of these 2 effects should give a solid boost to our sales in dermatology. We secured the podium space at the Anti-Aging Congress in Monte Carlo, which takes place about 1 month from now. And we have high hopes for the MonaLisa glide device. And for the DUOGlide device, these are the main ones. DUOGlide is the device that adds 2 wavelengths, one new wavelength, to the traditional CO2 wavelength. As for the acne device, I don't have any genuinely new information to share today. The clinical studies are moving forward. The funding is in place for the company.

Andrea Cangioli

executive
#40

The company managed to bring in a substantial amount of capital, and that money is what's funding the studies. For anyone who may not remember, from a technological standpoint the acne device's development has been carried out by our company Quanta System. When it came to application and regulatory matters, though, we concluded that the investment required was very large and carried a lot of risk, so we separated out the development of those aspects of the technology into a company named Accure Acne, where we hold a minority stake, since that company has been financed with capital from third parties. After the FDA clearance process is complete, this company ought to be in a position to bring in additional money and to speed things up -- to launch the product onto the market, and by that route build a very strong sales infrastructure using its own capital while generating a very strong flow of device sales from Quanta System to Accure Acne. Still, as I've consistently told investors, we are very near to securing the FDA clearance. We have gotten the CE Mark, which matters a great deal, yet it isn't sufficient to achieve solid commercial success for a device like this. But we don't have the clearance yet.

Andrea Cangioli

executive
#41

So even with a lot of confidence in the team handling this clearance, there's no guarantee that we'll actually get it. I hope that covers everything you asked, Andrea.

Bianca Fersini Mastelloni

operator
#42

Andrea, there’s another question coming in from Francois Robillard.

François Robillard

analyst
#43

Yes, just a quick follow-up regarding the potential Chinese IPO. If I remember right, you hold roughly 85% of the local company. I'd just like a bit more detail on why you'd do such a transaction. Would it involve a capital increase to raise additional funding, or would it be a partial exit from your local investment? And if that's the case, what would you use the proceeds from such a deal for? And just to learn a little more about the Chinese operations — I believe revenues for 2021 came in at around EUR 140 million in sales. What kind of profitability are we looking at in this market?

Andrea Cangioli

executive
#44

Thank you for that question — it lets me share a bit more detail, as far as I'm able to. We don't have a definite IPO project at this point, and the view they've expressed is an opportunity that's been outlined, but nothing firm yet. So I can't tell you what the IPO would be. Broadly speaking, what I understand is that IPOs in Chinese territory involve selling roughly 25% of the capital — sorry, not selling — issuing new shares worth 25% of the capital. That's the opportunity a possible IPO would give our business — for developing the business. Profitability in that business is quite low, and it was quite low in 2020. Why do I say quite low? If you compare it with the profitability we can achieve in the medical business. In fact, we're having better success in Italy in 2021 than in China, because of the situation that, as I mentioned earlier, should cool down somewhat over the year — over the second half of the year.

Andrea Cangioli

executive
#45

Regarding our overall revenue, and Enrico can give more detail on China specifically, I think we should anticipate an EBIT margin in the near term of somewhere between 5% and 8%, and that depends on how much volume we can actually sell, since profitability in this business is heavily tied to the leverage effect. As you're aware, we operate 5 factories. Our fixed costs are fairly substantial. So the capacity to grow revenue, and thereby gain that leverage effect, has a very, very strong impact on the bottom line. Because of that, and given that the second half of the year wasn't especially favorable, China saw a lower EBIT than usual in 2021. Meanwhile, in that same division, which also covers the Italian activity, helped by the outstanding performance of the Italian facility, which surpassed EUR 80 million in revenue in 2021 and came closer in profitability to the profitability standards of the rest of the group.

Enrico Romagnoli

executive
#46

Andrea, for the Chinese consolidated business, total sales came to EUR 143 million.

Andrea Cangioli

executive
#47

And as for the consolidated figure for the cutting business, which covers both systems and service?

Enrico Romagnoli

executive
#48

Let me see.

Andrea Cangioli

executive
#49

Two hundred and a bit.

Enrico Romagnoli

executive
#50

Yeah, just give me a moment here — EUR 223 million.

Andrea Cangioli

executive
#51

Thanks.

Bianca Fersini Mastelloni

operator
#52

Andrea, there’s another question coming from Andrea Bonfa.

Andrea Bonfà

analyst
#53

Andrea, going back to the acne device and the FDA approval — does your guidance include any revenue from that possible approval, or is all of it upside? That's the first question. And then, could you comment on the U.S. dollar — at this level, is it helpful for you?

Andrea Cangioli

executive
#54

When it comes to acne sales, the figure in the 2022 budget comes out to 0.

Andrea Bonfà

analyst
#55

Alright.

Andrea Cangioli

executive
#56

On the dollar — actually, you're right, I should have brought that up. Right now, we're at an exchange rate of roughly $1.10 against the U.S. dollar. Needless to say, that's a big help to us relative to last year's average foreign exchange rate, and also relative to the controlled foreign exchange at the end of the year. So again, if foreign exchange stays in this area for longer, we'd have a significant advantage on margins, since a good part of the sales growth in 2022 — particularly in the aesthetics market — comes from sales that are expressed in U.S. dollars. And so again, if the dollar remains where it is now, we could see very positive surprises. Let's say even if it isn't a surprise, we could model a nice shape for our profitability. But of course, it's one of those things that are somehow a consequence of the world. We've seen how the dollar strengthened in the days right after the war. I'd remind everybody, and remind you, that not only do we make more money in the trade agreements where we're setting prices in dollars, but also we gain competitive advantage against most of our competitors that are competing in dollars, and we become more competitive worldwide.

Andrea Cangioli

executive
#57

And because of that — a strong dollar always benefits how competitive we are around the world.

Andrea Bonfà

analyst
#58

And if I could just follow up on China. If I recall correctly, your main business involves cutting sheet metal. But with the higher power you're able to deliver, you can also move into rod bars, which basically means construction. Okay, we're all aware that construction in China is, let's say, struggling at the moment, but is it fair to assume that any sales in that sector would come on top of your business, which previously was essentially 0?

Andrea Cangioli

executive
#59

It is. You've seen that clip I keep showing. This is sheet metal — 4 centimeters thick, but it's still sheet metal regardless. Naturally, though, you wouldn't make this sheet metal the backbone of a smartphone, because <<inaudible>>. You're correct that the construction market in China is described as rather slow for a number of reasons. Still, we're coming into that market as one more market for us. We can shift it, and we're counting on existing devices being replaced. What happens is that, if the assumption we hold proves out, if the work we're doing is in fact validated, then a construction player that has to cut metal like what you saw earlier will be pushed in that direction, and we hold major advantages when a laser system is purchased, since it brings both a cost benefit and a flexibility benefit across all of that player's production facilities. So the innovation is something that, naturally, a positive cycle helps along. Yet it might turn into something required if, as we hope, the benefits of taking up a laser system prove so substantial for that type of application.

Bianca Fersini Mastelloni

operator
#60

And Andrea, our list doesn't have any further questions. I'd like to check with the floor — is anyone else holding a question? If nothing more comes in, we'll wrap up this conference here. Should you have anything you'd like to look into, feel free to reach out to Enrico Romagnoli, and he'll gladly answer whatever you ask. Thanks for joining this conference, and we hope to see all of you again next time. Good afternoon, everyone.

Andrea Cangioli

executive
#61

Appreciate it.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.